CD274 and non-small cell lung carcinoma: In the last decade, ICIs have become an essential component of front-line systemic treatment of advanced non-oncogene addicted NSCLC, achieving a doubled rate of long-term survivors among patients strongly expressing PD-L1 who received pembrolizumab (5-year OS 31.9%, 95% CI 24.5–39.5) vs. standard chemotherapy (5-year OS 16.3%, 95% CI 10.6–23.0) from the breakthrough Keynote-024 trial [86].